Glasgow 2024 included 48-week results from a randomised placebo-controlled phase 2 switch study comparing once-weekly islatravir plus lenacapavir (ISL+LEN) to a control group who continued on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF).
If effective, once-weekly dosing has the potential to improve quality of life much more easily than injectable formulations, and without the need to reorganise clinic services.
Read the full report by Simon Collins, HIV i-Base here.
All HIV i-Base reports from HIV Glasgow 2024 can be accessed here.
Source : HIV i-Base
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.